3.155

1.95% 0.065

Prime Medicine Inc (PRME)

Overview News Price History Option Chain Financials Discussions Forecast

Prime Medicine Inc stock is traded at $3.155, with a volume of 990.30K. It is up +1.95% in the last 24 hours and up +0.65% over the past month. Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Previous Close:

$3.09

Open:

$3.07

24h Volume:

990.30K

Relative Volume:

0.31

Market Cap:

$573.15M

Revenue:

$4.03M

Net Income/Loss:

$-198.37M

P/E Ratio:

-2.5139

EPS:

-1.255

Net Cash Flow:

$-158.74M

1W Performance:

+0.01%

1M Performance:

+0.65%

6M Performance:

-4.83%

1Y Performance:

-11.76%

1-Day Range:

$3.0205

$3.1788

1-Week Range:

$3.00

$3.305

52-Week Range:

$2.67

$6.94

Prime Medicine Inc Stock (PRME) Company Profile

Name

Prime Medicine Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

617-465-0013

Address

60 FIRST ST., CAMBRIDGE

Employee

146

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

PRME's Discussions on Twitter

Compare PRME vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRME Prime Medicine Inc	3.16	560.45M	4.03M	-198.37M	-158.74M	-1.255
VRTX Vertex Pharmaceuticals Inc	515.94	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	807.13	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	991.78	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	213.72	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.77	39.31B	5.76B	514.49M	1.10B	4.4813

Prime Medicine Inc Stock (PRME) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-26	Initiated	Oppenheimer	Outperform
May-27-25	Downgrade	Citigroup	Buy → Neutral
May-20-25	Downgrade	H.C. Wainwright	Buy → Neutral
May-20-25	Downgrade	JP Morgan	Overweight → Neutral
Dec-10-24	Initiated	JMP Securities	Mkt Outperform
May-20-24	Initiated	H.C. Wainwright	Buy
May-16-24	Upgrade	Citigroup	Neutral → Buy
Apr-22-24	Initiated	Chardan Capital Markets	Buy
Apr-08-24	Initiated	TD Cowen	Buy
Apr-03-24	Initiated	Wedbush	Outperform
Jan-16-24	Downgrade	Stifel	Buy → Hold
Dec-08-23	Initiated	Citigroup	Neutral
Oct-09-23	Initiated	BMO Capital Markets	Outperform
Jul-31-23	Initiated	Guggenheim	Buy
Apr-18-23	Initiated	Stifel	Buy
Nov-14-22	Initiated	Goldman	Neutral
Nov-14-22	Initiated	JP Morgan	Overweight
Nov-14-22	Initiated	Jefferies	Buy
Nov-14-22	Initiated	Morgan Stanley	Equal-Weight

View All

Prime Medicine Inc Stock (PRME) Latest News

Aug 15, 2026

Prime Medicine: Soon In The Clinic (NASDAQ:PRME) - Seeking Alpha

Aug 15, 2026

Prime Medicine, Inc. Stock 12‑Month Price Target Cut to $6.92, Implies 124% Upside - TradingView

Aug 15, 2026

Aug 12, 2026

Q3 EPS Estimates for Prime Medicine Boosted by HC Wainwright - marketbeat.com

Aug 12, 2026

Aug 11, 2026

Prime Medicine: An Initial Prognosis (NASDAQ:PRME) - Seeking Alpha

Aug 11, 2026

Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR) - The Globe and Mail

Aug 11, 2026

Aug 10, 2026

Prime Medicine (NASDAQ:PRME) Trading Up 7.3%Still a Buy? - marketbeat.com

Aug 10, 2026

Prime Medicine's (PRME) "Buy" Rating Reaffirmed at HC Wainwright - marketbeat.com

Aug 10, 2026

Weekly Recap: Q2 loss/runway into 2027 and PM647 arbitration win, IND Q3 - TradingView

Aug 10, 2026

H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Aug 10, 2026

Renaissance Technologies LLC Sells 408,120 Shares of Prime Medicine, Inc. $PRME - marketbeat.com

Aug 10, 2026

Aug 08, 2026

Prime Medicine (NASDAQ:PRME) Stock Rating Upgraded by Wall Street Zen - marketbeat.com

Aug 08, 2026

Aug 06, 2026

Prime Medicine (NASDAQ:PRME) Announces Earnings Results, Meets Estimates - MarketBeat

Aug 06, 2026

JonesTrading Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Aug 06, 2026

Prime Medicine, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 06, 2026